Suppr超能文献

日本生长激素缺乏症儿童成人身高的国际比较及生长激素治疗的局限性

International Comparison of Adult Height in Children with Growth Hormone Deficiency and Limitations of Growth Hormone Treatment in Japan.

作者信息

Tanaka Toshiaki

机构信息

Tanaka Growth Clinic, Famille Yoga 1F, 2-36-7 Yoga, Setagaya-ku, Tokyo, Japan.

出版信息

Pediatr Endocrinol Rev. 2017 Mar;14 Suppl 1(Suppl 1):216-221. doi: 10.17458/per.vol14.2017.t.internationalcomparison.

Abstract

The approved therapeutic dose of growth hormone (GH) for growth hormone deficiency (GHD) varies depending on the country. Japan has the lowest therapeutic dose globally, with a single dose of 0.175 mg/kg/week. GH treatment for GHD is considered as a replacement therapy and in fact, a dose of 0.175 mg/kg/week is slightly higher than GH secretion in prepubertal healthy children but nearly the same as that of pubertal children. Although the same growth rate as that of healthy children is expected in response to replacement therapy, the catch-up growth observed for the first 1 to 2 years of GH treatment was misinterpreted as an effect of the GH replacement therapy. The real effect of the GH replacement therapy was the growth rate appeared after more than 3 years of GH therapy, when patients showed nearly the same growth rate as healthy children. Therefore, children with GHD can have a higher growth rate than healthy children only for the first 1 to 2 years of GH therapy, after which their growth rate begins to wane. In the United States and Europe, the various therapeutic doses and high-dose treatment are accepted and the SD score of adult height after treatment is higher than that in Japan. The improvement degree of the height SD score and the adult height SD score with GH therapy are lower in Japan compared with other countries that administer a similar therapeutic dose. This suggests that the response to GH can be affected by race. Actual comparison of the response to GH between Japanese and Caucasian patients using KIGS (Pharmacia International Growth Database) data showed that both the short-term response and the effect on adult height were reduced in Japanese patients. As there is a strong positive correlation between adult height and height at the onset of puberty, treatment methods that can increase pubertal growth will be considered in the future for patients with GDH who enter puberty with short stature.

摘要

生长激素(GH)治疗生长激素缺乏症(GHD)的批准治疗剂量因国家而异。日本的治疗剂量在全球最低,单次剂量为0.175mg/kg/周。GH治疗GHD被视为替代疗法,实际上,0.175mg/kg/周的剂量略高于青春期前健康儿童的GH分泌量,但与青春期儿童的分泌量几乎相同。尽管期望替代疗法能带来与健康儿童相同的生长速度,但GH治疗最初1至2年观察到的追赶生长被误解为GH替代疗法的效果。GH替代疗法的真正效果是在GH治疗超过3年后出现的生长速度,此时患者的生长速度与健康儿童几乎相同。因此,GHD儿童仅在GH治疗的最初1至2年生长速度可能高于健康儿童,之后其生长速度开始下降。在美国和欧洲,各种治疗剂量和高剂量治疗都是被接受的,治疗后成人身高的标准差评分高于日本。与其他使用类似治疗剂量的国家相比,日本GH治疗后身高标准差评分和成人身高标准差评分的改善程度较低。这表明对GH的反应可能受种族影响。使用KIGS(法玛西亚国际生长数据库)数据对日本和白种人患者对GH的反应进行实际比较发现,日本患者的短期反应和对成人身高的影响均降低。由于成人身高与青春期开始时的身高之间存在很强的正相关,未来对于青春期时身材矮小的GDH患者,将考虑能增加青春期生长的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验